Rintaro Hojo1, Seiji Fukamizu2, Takeshi Kitamura2, Yuya Aomyama2, Mitsuhiro Nishizaki3, Yoichi Kobayashi4, Harumizu Sakurada5, Masayasu Hiraoka6. 1. Department of Cardiology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. Electronic address: rinrintaro1979@hotmail.co.jp. 2. Department of Cardiology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. 3. Department of Cardiology, Yokohama Minami Kyosai Hospital, Yokohama, Japan. 4. Department of Cardiology, Showa University School of Medicine Hospital, Tokyo, Japan. 5. Tokyo Metropolitan Health and Medical Treatment Corporation Ohkubo Hospital, Tokyo, Japan. 6. Tokyo Medical and Dental University, Tokyo, Japan.
Abstract
OBJECTIVES: The aim of this paper was to clarify the impact of nonpulmonary vein foci (NPVF) on atrial fibrillation (AF) recurrence after pulmonary vein (PV) isolation. BACKGROUND: NPVF are considered contributing factors for the recurrence of AF after PV isolation, but their exact role remains unclear. METHODS: We retrospectively reviewed 216 patients (paroxysmal AF, n = 172; persistent AF, n = 44) who underwent a second electrophysiological study 6 months after the original PV isolation. Patients with AF recurrence underwent additional ablation procedures for reconnected PV and NPVF. NPVF were detected in the control group and with drug infusion (isoproterenol or isoproterenol with adenosine triphosphate) during the first and second procedure. NPVF detected for the first time in the second session were defined as newly developed, and their effect on AF recurrence after the second procedure was investigated, along with the predictive factors for NPVF development. RESULTS: Patients with AF recurrence after the first session had a significantly higher reconnected PV (91.5% vs. 68.2% in patients without recurrence). NPVF were detected in 20 and 54 patients in the first and second sessions, respectively. Patients with newly developed NPVF had a significantly higher AF recurrence (24.1% vs. 7.4% in patients without newly developed NPVF). Newly developed NPVF and AF recurrence after the first session were independent predictors for AF recurrence after the second procedure, whereas AF history and NPVF in the first session were independent predictors for newly developed NPVF. CONCLUSIONS: NPVF detection and ablation may represent important therapeutic options to prevent AF recurrence, especially in patients who require repeated procedures.
OBJECTIVES: The aim of this paper was to clarify the impact of nonpulmonary vein foci (NPVF) on atrial fibrillation (AF) recurrence after pulmonary vein (PV) isolation. BACKGROUND: NPVF are considered contributing factors for the recurrence of AF after PV isolation, but their exact role remains unclear. METHODS: We retrospectively reviewed 216 patients (paroxysmal AF, n = 172; persistent AF, n = 44) who underwent a second electrophysiological study 6 months after the original PV isolation. Patients with AF recurrence underwent additional ablation procedures for reconnected PV and NPVF. NPVF were detected in the control group and with drug infusion (isoproterenol or isoproterenol with adenosine triphosphate) during the first and second procedure. NPVF detected for the first time in the second session were defined as newly developed, and their effect on AF recurrence after the second procedure was investigated, along with the predictive factors for NPVF development. RESULTS:Patients with AF recurrence after the first session had a significantly higher reconnected PV (91.5% vs. 68.2% in patients without recurrence). NPVF were detected in 20 and 54 patients in the first and second sessions, respectively. Patients with newly developed NPVF had a significantly higher AF recurrence (24.1% vs. 7.4% in patients without newly developed NPVF). Newly developed NPVF and AF recurrence after the first session were independent predictors for AF recurrence after the second procedure, whereas AF history and NPVF in the first session were independent predictors for newly developed NPVF. CONCLUSIONS: NPVF detection and ablation may represent important therapeutic options to prevent AF recurrence, especially in patients who require repeated procedures.
Authors: Jim W Cheung; Edward P Cheng; Xian Wu; Ilhwan Yeo; Paul J Christos; Hooman Kamel; Steven M Markowitz; Christopher F Liu; George Thomas; James E Ip; Bruce B Lerman; Luke K Kim Journal: Eur Heart J Date: 2019-09-21 Impact factor: 29.983
Authors: Sven Knecht; Ivan Zeljkovic; Michael Kühne; Christian Sticherling; Patrick Badertscher; Philipp Krisai; Florian Spies; Jan Vognstrup; Nikola Pavlovic; Sime Manola; Stefan Osswald Journal: J Interv Card Electrophysiol Date: 2022-08-18 Impact factor: 1.759
Authors: Concepción Alonso-Martín; Santiago García Mancebo; Bieito Campos García; Jose Guerra Ramos; Zoraida Moreno Weidman; Francisco Méndez Zurita; Rodolfo Montiel Quintero; Andrés Betancur Gutiérrez; Xavier Viñolas; Enrique Rodríguez Font Journal: JACC Case Rep Date: 2021-12-15